The most common grade 3 or higher AEs in the trial of KATE2 (NCT02924883) were thrombocytopenia (13% in the atezolizumab versus 4% in the placebo group), increased aspartate aminotransferase (8% versus 3%), anemia (5% versus 0), neutropenia (5% versus 4%), and increased alanine aminotransferase (5% versus 3%) (Emens et al., 2020). The gene discussed is GPT; the disease is anemia.